Daniel Ren Yi Yap

Daniel Ren Yi Yap

Auto-generated profile, based on publicly available information

Daniel Ren Yi Yap

Lee Kong Chian School of Medicine Nanyang Technological University Singapore Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
DYDaniel Ren Yi Yap
Daniel Ren Yi Yap
JWJolene Si Min Wong
Jolene Si Min Wong
QTQiu Xuan Tan
Qiu Xuan Tan
JTJoey Wee-Shan Tan
Joey Wee-Shan Tan
CCClaramae Shulyn Chia
Claramae Shulyn Chia
COChin-Ann JOhnny Ong
Chin-Ann JOhnny Ong
Background: Peritoneal metastasis (PM) is a late-stage manifestation of intra-abdominal malignancies. The current standard of care indicates that cure can only be achieved with cytoreductive surgery (CRS) which is often indicated with concurrent adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC). However, the utility of HIPEC within subsets of PM is not fully understood. We seek to compare the effectiveness of HIPEC in improving peritoneal recurrence rates in PM of different origins.Methods: We conducted a systematic review of trials on the PubMed, EMBASE, and Cochrane databases, last searched in August 2021. Biases were assessed using the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials as well as the Methodological Index for Non-Randomized Studies (MINORS) framework.Results: 7 gastric PM studies, 3 ovarian PM studies, and 3 colorectal PM studies were included. Recurrence-free survival was improved in the HIPEC + CRS cohort in 5 gastric trials but only 1 ovarian trial and none of colorectal origin.Discussion: Our findings indicate decent effectiveness of HIPEC in gastric PM, but limited utility in ovarian and colorectal PM. Limitations in the current literature are attributed to the paucity of data available, a lack of homogeneity and consideration of novel and personalised treatment regimens. We implore for further studies to be conducted with a focus on patient selection and stratification, and suggest a reframing of approach towards modern molecular and targeted therapeutic options in future studies of HIPEC.Systematic Review Registration: https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/60c1ffff0c1b78001e8efbe3/, identifier reviewregistry1166.

1 February 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
DYDaniel Ren Yi Yap
Daniel Ren Yi Yap
Rashid Nok Shun LuiRashid Nok Shun Lui
Rashid Nok Shun Lui
JSJens Samol
Jens Samol
JNJoanne Ngeow
Joanne Ngeow
JSJoseph JY Sung
Joseph JY Sung
SWSunny Wong
Sunny Wong
The role of appendectomy in the pathogenesis of colorectal cancer (CRC) is a recent topic of contention. Given that appendectomy remains one of the most commonly performed operations and a first‐line management strategy of acute appendicitis, it is inherently crucial to elucidate the association between prior appendectomy and subsequent development of CRC, as there may be long‐term health repercussions. In this review, we summarize the data behind the relationship of CRC in post‐appendectomy patients, discuss the role of the microbiome in relation to appendectomy and CRC pathogenesis, and provide an appraisal of our current understanding of the function of the appendix. We seek to piece together the current landscape surrounding the microbiome and immunological changes in the colon post‐appendectomy and suggest a direction for future research involving molecular, transcriptomic, and immunologic analysis to complement our current understanding of the alterations in gut microbiome.

1 January 2020 in Journal of Hematology
Verified
Journal Article
Open access
DYDaniel Ren Yi Yap
Daniel Ren Yi Yap
GTGrace Fangmin Tan
Grace Fangmin Tan
ECEsther Wei Yin Chang
Esther Wei Yin Chang
VYValerie Shiwen Yang
Valerie Shiwen Yang
EPEileen Yi Ling Poon
Eileen Yi Ling Poon
JCJason Yongsheng Chan
Jason Yongsheng Chan
Plasmablastic lymphoma (PBL) is an aggressive subtype of mature B-cell non-Hodgkin lymphoma. Given its rarity, there remains a lack of clinicopathological data to guide its management, particularly on Asian patients. We conducted a retrospective chart review of 10 patients diagnosed with PBL at the National Cancer Centre Singapore and performed a literature review of similar studies on Asian cohorts. Most patients were male (n = 9), with median age at diagnosis of 55 years (range, 33 - 91 years). Seven (70%) patients were considered to be immunocompromised. In the overall cohort, the median overall survival (OS) was 19.4 months with 5-year survival estimates given at 60% and 36% for OS and progression-free survival (PFS), respectively. At diagnosis, patients with HIV/AIDS (n = 5) were younger compared to others (median, 43 vs. 61 years; P = 0.0278), had greater number of nodal site involvement (median, 6 vs. 0; P = 0.0333), and higher international prognostic index (IPI) scores (P = 0.034 for trend). Amongst different chemotherapy used, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH)-based regimens (n = 6) elicited prominent complete response rates (83%) and led to durable responses even in the setting of advanced stage, high-risk IPI score and immunodeficiency. In conclusion, our study describes the features of PBL in an Asian cohort and highlights disease features unique to HIV-associated PBL.